Regulatory – ASCELIA

All All press releases Regulatory press releases Financial reports

Regulatory

2021-04-09 | Issue and repurchase of series C shares for share saving program

Regulatory

2021-03-31 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB

Regulatory

2021-03-31 | Number of shares and votes in Ascelia Pharma AB

Regulatory

2021-03-30 | Ascelia Pharma publishes Annual Report for 2020

Regulatory

2021-03-17 | Notice of extraordinary general meeting in Ascelia Pharma

Regulatory

2021-03-17 | Ascelia Pharma has carried out a directed new share issue raising SEK 200 million

Regulatory

2021-03-17 | Ascelia Pharma intends to carry out a directed new share issue

Regulatory

2021-02-16 | Quarterly Report Q4 2020: Mangoral shows high diagnostic value in new study

Regulatory

2020-12-15 | Ascelia Pharma gets US patent for second generation Mangoral

Regulatory

2020-12-02 | New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent

Regulatory

2020-11-05 | Quarterly Report Q3-2020: Raised market estimate for Mangoral and preparing for market launch

Regulatory

2020-10-21 | Upgraded estimate of addressable market for Mangoral to $500-600 million annually

Regulatory

2020-08-20 | Quarterly Report Q2-2020: First participant in the hepatic study

Regulatory

2020-07-31 | Change in number of shares and votes in Ascelia Pharma AB

Regulatory

2020-06-30 | Ascelia Pharma completes a directed new share issue of 4,697,781 shares, raising approximately SEK 98.7 million

Regulatory

2020-05-20 | Updated SPARKLE timelines due to Covid-19 impact

Regulatory

2020-05-13 | Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE

Regulatory

2020-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2020

Regulatory

2020-05-06 | First participant enrolled in the clinical hepatic impairment study with Mangoral

Regulatory

2020-04-06 | Ascelia Pharma publishes Annual Report for the financial year 2019